The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes—calling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA. As DEA prepares to […]